top of page

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment f

AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA's Fast Track programme is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.


Click on this link for more information.

source: http://www.worldpharmanews.com/astrazeneca/3594-astrazeneca-and-lilly-receive-fda-fast-track-designation-for-azd3293-an-investigational-treatment-for-early-alzheimer-s-disease

#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page